MiR-181a, upregulated in MI, is an important regulatory factor of the aldosterone–mineralocorticoid receptor (Aldo–MR) pathway, which drive cardiac arterial stiffness, fibrosis, hypertrophy, and cardiac remodeling by promoting inflammation and oxidative stress, which were involved in its downstream factors such as NGAL (lipocalin-2) (40, 93, 94). This evidence concerns the gene LCN2 and myocardial infarction.